Celosome Mid HA Filler
Next-generation hyaluronic acid dermal filler with HENMâ„¢ cross-linking technology | BDDE-free formulation | 98.7% purity certified
Advanced HENM Cross-Linking Technology
Celosome Mid utilizes patented High-Efficiency Nanoscale Modulation (HENMâ„¢) technology (KR Patent 1020210034567) to achieve precise G’-values ranging from 150Pa to 650Pa. The triple purification process removes 99.98% of BDDE residues (HPLC-verified) and reduces endotoxin levels to <0.05EU/ml. With 24mg/ml of non-animal stabilized HA and optimized particle size distribution (80-450μm), it demonstrates 18-month persistence in 89% of clinical cases (n=1,542).
Key Clinical Advantages
Precision Viscoelasticity
5 distinct formulations with G’ values optimized for specific facial layers (dermal to supraperiosteal)
Enhanced Safety Profile
0% BDDE residues | <0.3% swelling rate in phase III trials (n=893)
Longevity Optimized
Median duration 14.5 months in nasolabial folds | 82% persistence at 12 months
Rapid Recovery
94% patients resume normal activity within 24 hours (VAS score ≤2)
Product Specifications
- Composition: 24mg/ml HA + 0.3% Lidocaine
- Cross-linker: HENMâ„¢ technology (BDDE-free)
- Particle Size: 80-450μm (monodisperse distribution)
- Packaging: 1×1.1ml sterile syringe
- Certifications: ISO 13485, KFDA Class III
- Storage: Room temperature (2-25°C)
Clinical Protocol
- Needle: 27G-30G cannula recommended
- Depth: Mid-dermis to supraperiosteal layer
- Technique: Linear threading or fan pattern
- Max Volume: 2ml per session
- Anesthesia: Pre-incorporated lidocaine
Optimal Treatment Applications
Deep Wrinkle Correction
For nasolabial folds: Inject 0.4-0.8ml using 27G needle at mid-deep dermis. 92% patient satisfaction at 6 months (FWS-7 scale).
Volumetric Augmentation
Cheek enhancement: 1.2-2.0ml per side using blunt cannula. Maintains 89% volume retention at 12 months.
Contour Refinement
Jawline definition: 0.5-1.2ml per side with 25G needle. Optimal G’ of 450Pa for structural support.
Clinical Notice
Important: Results may vary based on individual tissue characteristics and injection technique. Must be administered by licensed aesthetic practitioners. Contraindicated for patients with active skin infections or known hypersensitivity to lidocaine.
Post-treatment monitoring required for vascular compromise signs. Avoid MRI for 4 weeks post-procedure. Not recommended for lip augmentation or glabellar regions.
Reviews
There are no reviews yet.